此外，公告指出，伴随着全民医保的深入推进与医学影像技术的广泛应用，我国造影剂需求旺盛，造影剂具有广阔的应用前景。2022年，中国造影剂市场规模超过百亿人民币。China Sino Biopharmaceutical (01177) rose by more than 3%, as of press time, up 3.28% at HKD 2.83, with a turnover of HKD 70.589 million.
According to the Zhitong Financial APP, China Sino Biopharmaceutical (01177) rose by more than 3%, as of press time, up 3.28% at HKD 2.83, with a turnover of HKD 70.589 million.
On the news front, China Sino Biopharmaceutical announced that its medical imaging product, Gadodiamide Injection (trademark: Daxian), has obtained the approval for listing from the China National Medical Products Administration.
In addition, the announcement pointed out that with the deepening of the universal healthcare and the widespread application of medical imaging technology, the demand for contrast agents in China is strong, and contrast agents have broad application prospects. By 2022, China's contrast agent market will exceed 10 billion yuan.
